Analysts’ Weekly Ratings Updates for Benitec Biopharma (BNTC)

Several analysts have recently updated their ratings and price targets for Benitec Biopharma (NASDAQ: BNTC):

• 9/19/2026 – Benitec Biopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/15/2026 – Benitec Biopharma had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/15/2026 – Benitec Biopharma was upgraded by Royal Bank Of Canada to “outperform”.
• 9/15/2026 – Benitec Biopharma had its price target raised by Wedbush from $16.00 to $17.00. They now have an “outperform” rating on the stock.
• 8/1/2026 – Benitec Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/28/2026 – Benitec Biopharma is now covered by Wedbush. They set an “outperform” rating and a $16.00 price target on the stock.
• 7/28/2026 – Benitec Biopharma is now covered by Wedbush. They set an “outperform” rating and a $16.00 price target on the stock.

Benitec Biopharma Inc (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on DNA-directed RNA interference (ddRNAi). The company’s technology is designed to enable long-lasting suppression of disease-causing genes by delivering genetic instructions that produce RNA interference molecules within targeted cells.

Benitec’s lead product candidate is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD), a rare inherited disorder that can cause progressive weakness of the muscles involved in swallowing and eye movement.